Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)
Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts on non–small cell lung cancer: alectinib vs crizotinib in treatment-naive advanced ALK+ disease, and dacomitinib vs gefitinib for first-line treatment of advanced EGFR+ disease. (Abstracts LBA9008 and LBA9007)
Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)
Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal canal compression. (Abstract LBA10004)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)
